FDA Issues Approvable Letter for CUBICIN sNDA - Research and Markets offers a brief of 'Cubist Pharmaceuticals, Inc.' Conference Call.

DUBLIN Dublin, city, Republic of Ireland
Dublin, Irish Baile Átha Cliath, county borough (1991 pop. 915,516), Leinster, capital of the Republic of Ireland, on Dublin Bay at the mouth of the Liffey River. , Ireland -- The Cubist Pharmaceuticals, Inc. (NASDAQ NASDAQ
in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :CBST CBST Center for Biophotonics Science and Technology
CBST Congregation Beth Simcha Torah (NYC)
CBST Complete Binary Search Tree ) Corporate Conference Call took place on 24-Mar-06 7:00pm ET.

CBST is disappointed that it has not been able to reach agreement on the label. Next week, the Co. plans to commence a process with the FDA FDA
abbr.
Food and Drug Administration

FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration. to resolve these label negotiations within 60 days.

More information on this Conference Call can be obtained from Research and Markets at http://www.researchandmarkets.com/transcripts/83587

This document provides a non-biased summary of the conference call detailing the key points and the full Q&A session.

COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.

Reader Opinion

Article Details
Printer friendly Cite/link Email Feedback
Publication:	Business Wire
Geographic Code:	1USA
Date:	Mar 28, 2006
Words:	93
Previous Article:	Fitch Upgrades East Baton Rouge Parish, Louisiana's Sewer Sales Tax Revs to 'A+'.
Next Article:	H.B. Fuller Reports First Quarter Results and Raises Expectations for Fiscal Year 2006.
Topics:	Administrative agencies Government agencies Pharmaceutical industry

Related Articles
FDA Issues Approvable Letter for Daytrana(TM) Methylphenidate Transdermal System.
Review of Cubist Pharmaceuticals sNDA for CUBICIN Moves Forward at FDA; Anti-infective Drugs Advisory Committee to meet March 6.
Cubist Pharmaceuticals Announces Posting of Briefing Documents for FDA Anti-Infective Drugs Advisory Committee (AIDAC) Meeting; AIDAC Meeting to...
Cubist Pharmaceuticals Reports Positive Outcome from FDA Anti-Infective Drugs Advisory Committee; PDUFA Date for FDA Review of CUBICIN sNDA is March...
FDA Issues Approvable Letter for CUBICIN sNDA; Conference Call Scheduled For 7:00 PM E.T. Today.
Cubist Pharmaceuticals Has Submitted Response to FDA Approvable Letter Received on Friday; FDA Action Anticipated by Late May.
Cubist Pharmaceuticals to Announce First Quarter 2006 Financial Results on Wednesday, April 19th, 2006.
Cubist Pharmaceuticals Reports First Quarter 2006 Results; Total Revenues $40.1 Million; Net Product Revenues $37.9 Million.
FDA Approves Expanded Label for IV Antibiotic CUBICIN(R) to Add Bloodstream Infections Including Right-Sided Infective Endocarditis Caused by MSSA...
FDA Issues Approvable Letter for Entereg(R) (alvimopan) for POI.